Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology
Reexamination Certificate
2011-06-21
2011-06-21
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of regulating cell metabolism or physiology
Reexamination Certificate
active
07964400
ABSTRACT:
A composition of matter is disclosed, comprising an immunostimulatory molecule and animal cells cultured in the presence of at least one interferon (IFN) for a time and under conditions sufficient to enhance the antigen presenting function of said cells. Also disclosed are immunopotentiating compositions and their use for treatment and/or prophylaxis of a disease or condition.
REFERENCES:
patent: 5711425 (1998-01-01), Trimble-Gomez et al.
patent: 5858776 (1999-01-01), Ostrand-Rosenberg et al.
patent: 5993828 (1999-11-01), Morton
patent: 6039941 (2000-03-01), Blankenstein et al.
patent: 6183734 (2001-02-01), Chen et al.
patent: 6207170 (2001-03-01), Popescu et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6277368 (2001-08-01), Hiserodt et al.
patent: 6319709 (2001-11-01), Ostrand-Rosenberg et al.
patent: 6451305 (2002-09-01), Boussiotis et al.
patent: 6828150 (2004-12-01), Cai et al.
patent: 7011833 (2006-03-01), Sturmhoefel et al.
patent: 7455846 (2008-11-01), Ralph
patent: 2001/0012517 (2001-08-01), Popescu et al.
patent: 2002/0034500 (2002-03-01), Levings et al.
patent: 2002/0155135 (2002-10-01), Popescu et al.
patent: 2003/0092177 (2003-05-01), Belardelli et al.
patent: 1067194 (2001-01-01), None
patent: 1291414 (2003-03-01), None
patent: WO 94/21808 (1994-09-01), None
patent: WO 97/00085 (1997-01-01), None
patent: WO 98/23728 (1998-06-01), None
patent: WO 99/15199 (1999-04-01), None
patent: WO 99/61051 (1999-12-01), None
patent: WO 00/04918 (2000-02-01), None
patent: WO 00/31138 (2000-06-01), None
patent: WO 00/44880 (2000-08-01), None
patent: WO 01/15728 (2001-03-01), None
patent: WO 01/95919 (2001-12-01), None
patent: WO 02/36769 (2002-05-01), None
patent: WO 03/045427 (2003-06-01), None
Denfeld, R.W. et al. 1995 “In Situ Expression of B7 and CD28 Receptor Families in Human Malignant Melanoma: Relevance for T-Cell-Mediated Anti-Tumor Immunity”Int. J. Cancer62:259-265.
Morandini, R. et al. 1998 “Modulation of ICAM-1 Expression by α-MSH in Human Melanoma Cells and Melanocytes”Journal of Cellular Physiology175:276-282.
Abril et al.,(1998) “Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line,”Cancer Immunol. Immunother47:113-120.
Allison et al. 1995 “Manipulation of costimulatory signals to enhance antitumor T-cell responses”Current Opinion in Immunology7:682-686.
Aman et al., (1990) “An Epstein-Barr virus immortalization associated gene segment interferes specifically with the IFN-induced anti-proliferative response in human B-lymphoid cell lines,”EMBO9:147-152.
Attwood, T. 2000 “Genomics. The Babel of bioinformatics”Science290:471-473.
Baltz, J., (1995) “Vaccines in the treatment of cancer,”Am. J. Health-Syst. Phar., 52:2574-2585.
Billard et al., (1986) “Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells,”Blood67: 821-826.
Bohm et al., (1998) “T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas1”,J. Immunol. 161:897-908.
Bowie et al. 1990 “Deciphering the message in protein sequences: tolerance to amino acid substitutions”Science247:1306-1310.
Cavallo et al., (1995) “Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response,”Eur. J. Immunol. 25:1154-1162.
Chen et al., (1993) “Costimulation of T cells for tumor immunity,”Immunol Today14: 483-485.
Chen et al., (1994) “Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity,”J. Exp. Med. 179:523-532.
Chin et al., (1996) “Cell growth arrest and induction. of cyclin-dependent kinase inhibitor p21WAF1/CIP1mediated by STAT1,”Science272:719-722.
Chin et al., (1997) “Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis,”Mol. Cell. Biol. 17: 5328-5337.
Colamonici et al., (1992) “Correlation between interferon (IFN) α resistance and deletion of the IFN α/β genes in acute leukemia cell lines suggests selection against the IFN system,”Blood80: 744-749.
Coligan, J.E. et al., (1993) “In vitro assays for mouse lymphocyte function,” Chapt. 3 inCurrent Protocols in Immunology, Edited by Coligan et al., Greene Pub. Associates and Wiley-Interscience, New York. 3.0.1-3.15.12.
De Maeyer et al., (1988) “Induction of IFN-α and IFN-β”, Chapter 3 ofInterferons and other regulatory cytokines, John Wiley & Sons, New York, New York, pp. 39-66.
De Maeyer et al., (1988) “The effects of interferons on cell growth and division”, Chapter 7 ofInterferons and other regulatory cytokines, John Wiley & Sons, New York, New York, pp. 134-153.
De Maeyer et al., (1988) “The effects of interferons on tumor cells”, Chapter 14 ofInterferons and other regulatory cytokines, John Wiley & Sons, New York, New York, pp. 334-363.
Dezfouli, S. et al. (2003) “Enhancing CTL responses to melanoma cell vaccines in vivo:synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells” Immunology and Cell Biology 81:459-471.
Dols et al., (2003) “Allogeneic breast cancer cell vaccines,”Clin. Breast Cancer Suppl. 3: 173-180.
Dron et al., (1993) “Interferon-resistant Daudi cells are deficient in interferon-α-induced ISGF3α activation, but remain sensitive to the interferon-α-induced increase in ISGF3γ content,”J. Interferon Res. 13:377-383.
Gao, P.Q et al. (1993) “Interferon-gamma priming effects in the activation and deactivation of ISGF3 in K562 cells” Journal of Biological Chemistry 268:12380-12387.
Greenwand et al. 2005 “The B7 Family Revisited”Annu Rev Immunol23:515-548.
Guadagni, F. et al. (1989) “Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells” Journal of the National Cancer Institute 81:502-512.
Guo et al. 1994 “Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells”Science263:518-520.
Gutterman, J. (1994) “Cytokine therapeutics: lessons from interferon α,”PNAS USA., 91:1198-1205.
Haque et al., (1998) “Signal transduction in the interferon system,”Semin. Oncol. 25:14-22.
Hersey et al., (1994) “Expression of the co-stimulatory molecule B7 on melanoma cells,”Int. J. Cancer58:527-532.
Hertzog et al., (1988) “Interferons in rheumatoid arthritis: alterations in production and response related to disease activity,”Clin. Immunol. Immunopathol., 48:192-201.
Heyman et al., (1994) “Interferon system defects in malignant T-cells,”Leukemia8:425-434.
Honglian et al., “Induction of anti-hepatoma immunity by recombinant retrovirus expressing B7-1/B7-2 costimulatory molecules”,J Med Coll PLA, vol. 15(2), 2000: pp. 138-142.
Hsueh et al., (2002) “Active immunotherapy by reinduction with a polyvalent allergeneic cell vaccine correlates with improved survival in recurrent monastic melanoma,”Ann Surg Oncol9: 486-492.
Isaacs et al., (1957) “Virus interference. I. The interferon,”Proc. R. Soc. Lond. (Biol.) 147:258-267.
Johns et al., (1992) “Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β,”J. Natl. Cancer Inst. 84:1185-1120.
Kanda et al., (1992) “The EBNA2-related resistance towards alpha interferon (IFN-α) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3,”Mol. Cel. Biol. 12:4930-4936.
Kaplan et al., (1998) “Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Knobbe Martens Olson & Bear LLP
Ouspenski Ilia
Ralph Stephen John
LandOfFree
Immune potentiating compositions of cancer cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune potentiating compositions of cancer cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune potentiating compositions of cancer cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2693348